Back to Home
Video

Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection

Release Date

October 24, 2024

Expiration Date

October 25, 2025

Credits

1.0 CME

Specialties

Lung Cancer, Medical Oncology+7 more

Release Date: October 24, 2024

Expiration Date: October 24, 2025

Activity Overview

This educational activity is an archive of the live virtual presentation held on September 9th, 2024.

For more information about this educational activity, the faculty, and disclosures, please click here.

Target Audience

This educational activity is directed toward physicians, pathologists, nurses, nurse practitioners, physician assistants, pharmacists, and other health care professionals involved in the diagnosis and treatment of NSCLC.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Identify the genetic and molecular characteristics of driver mutations in NSCLC
  • Apply molecular testing strategies effectively to identify targetable mutations in clinical practice
  • Apply results of molecular profiling of NSCLC to individualized treatment plans for patients
  • Implement practices to facilitate real-time updates and adjustments to treatment plans based on evolving biomarker status
Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection

GET STARTED WITH THIS PROGRAM:

Register now to gain access to this program.

Create AccountAlready Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Novartis Pharmaceuticals Corporation and Rigel Pharmaceuticals, Inc.

Course

Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection

Create Account